In recent years, the description of cell populations with an anti-inflammatory function such as TCD4+reg, CD8+reg or Breg and their correlation to circulatory concentrations of IL-35 have been associated with the evolution of treatments in lung cancer [81]. This evidence concerns the gene CD8A and lung cancer.